SZTURZ, Petr a Jan B. VERMORKEN. Immunotherapeutic Approaches. In Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O'Sullivan. Critical Issues in Head and Neck Oncology. Switzerland: Springer International Publishing. s. 233-249. ISBN 978-3-319-42907-6. doi:10.1007/978-3-319-42909-0_15. 2017.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Immunotherapeutic Approaches
Autoři SZTURZ, Petr (203 Česká republika, garant, domácí) a Jan B. VERMORKEN (56 Belgie).
Vydání Switzerland, Critical Issues in Head and Neck Oncology, od s. 233-249, 17 s. 2017.
Nakladatel Springer International Publishing
Další údaje
Originální jazyk angličtina
Typ výsledku Kapitola resp. kapitoly v odborné knize
Obor 30200 3.2 Clinical medicine
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
Forma vydání tištěná verze "print"
Kód RIV RIV/00216224:14110/17:00096006
Organizační jednotka Lékařská fakulta
ISBN 978-3-319-42907-6
Doi http://dx.doi.org/10.1007/978-3-319-42909-0_15
Klíčová slova anglicky Head and neck cancer; Recurrent and metastatic; Immunotherapy; Immune escape; Immune checkpoint inhibitors; Pembrolizumab; Nivolumab; Durvalumab
Štítky EL OK, topvydavatel
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 11. 1. 2017 13:12.
Anotace
Although the first reports on a potential association between cancer and the immune system date back to the nineteenth century, the establishment of immunotherapy as an adequate anticancer treatment modality took more than 150 years to complete, being accompanied by many obstacles and challenges. The basic concept behind immunotherapy is to restore the natural anticancer potential of the immune system. In broad terms, immunotherapy includes tumour-specific monoclonal antibodies, cancer vaccines, adoptive cell transfer and immune-modulating antibodies (e.g. immune checkpoint inhibitors). Building on their success in advanced melanoma, immune checkpoint inhibitors have received major attention in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). Pembrolizumab, a monoclonal antibody against programmed death-1 (PD-1) receptor, has been tested in the phase Ib trial KEYNOTE-012 achieving overall response and disease control rates of 25 % and 50 %, respectively. In a phase I/II study with durvalumab, a monoclonal antibody against programmed death ligand-1 (PD-L1), overall response and disease control rates were 11 % and 15 %, respectively. PD-L1 (but possibly also PD-L2) expression and interferon-gamma signature have emerged as promising predictive biomarkers, yet to be prospectively validated. In April 2016, results from a planned interim analysis of the phase III trial CHECKMATE-141 showed a statistically significant improvement in median overall survival (7.5 versus 5.1 months; p = 0.0101) achieved with nivolumab, an anti-PD-1 monoclonal antibody, versus single-agent chemotherapy (methotrexate, docetaxel) or cetuximab, defining thus a new standard of care in platinum-refractory R/M-SCCHN. Due to its distinctive mechanism of action, immunotherapy may not be recommended for patients with comorbid autoimmune disorders and those requiring prompt symptom relief. At present, six other ongoing randomized trials explore immune checkpoint inhibitors in the R/M-SCCHN setting with results to be expected in the first half of 2017.
VytisknoutZobrazeno: 28. 3. 2024 09:04